Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission

Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of “Buy” by Brokerages

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Achieve Life Sciences Announces Up to $354 Million Private Placement

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Achieve Life Sciences: The Recent Sell Off Skews The Outcomes

Achieve Life Sciences: Maintaining 'Buy' On Upcoming PDUFA And Expansion Into Vaping Cessation

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript

Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

Achieve Life Sciences (ACHV) Expected to Announce Earnings on Tuesday

Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above 200 Day Moving Average – What’s Next?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Rating of “Moderate Buy” by Brokerages

Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch

Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200-Day Moving Average – Here’s Why

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Achieve Life Sciences (NASDAQ:ACHV) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Head-To-Head Survey: Achieve Life Sciences (NASDAQ:ACHV) vs. Carisma Therapeutics (NASDAQ:CARM)

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above 200-Day Moving Average – Here’s Why

Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript